Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-centre, open-label single-arm Phase 2 study of subcutaneous ILB in ALS
2017-005065-47Phase 2Terminated
- Sponsor
- TikoMed
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ilb in amyotrophic lateral sclerosis (ALS), sponsored by TikoMed. Primary endpoint: Safety and tolerability of subcutaneous ILB. Started Mar 2018; status: terminated.
02
Drugs
ilb
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2017-005065-47.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-005065-47.